Description:

The purpose of the study is to test the hypothesis that oral administration of ruboxistaurin will reduce the occurence of sustained moderate visual loss (SMVL) in patients with clinically significant macular edema. SMVL is defined as a 15 letter or more decrease from baseline in best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity that is sustained for the patient's last 6 months of study participation. The SMVL data from this study will be combined with the SMVL data from Study B7A-MC-MBDL for the purpose of comparing ruboxistaurin to placebo.

Keywords:
  1. 12/9/13 12/9/13 - Martin Dugas
Uploaded on:

December 9, 2013

DOI:
To request one please log in.
License :
Creative Commons BY-NC 3.0 Legacy
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00133952 # Diabetes Mellitus

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Einschlusskriterien
Healthy Volunteers
InclusionCriterion_1
IclusionCriterion_2
InclusionCriterion_3
InclusionCriterion_4
InclusionCriterion_5
Ausschlusskriterien
ExclusionCriterion_1
ExclusionCriterion_2
ExclusionCriterion_3
ExclusionCriterion_4
ExclusionCriterion_5
Medizinische Konzepte

Similar models

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial